2024-11-12T09:32:41-06:00 2023-12-31 582676261 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2023-01-01 061389829 Albert B Sabin Vaccine Institute Inc ALBE 2028428610 2000 Pennsylvania Avenue NW 7000 Washington DC 20006 Amy Finan Chief Executive Officer 2028428610 2024-11-12 1 1 Jie Chen CPA P01049760 7038930300 2023 2024-10-15 13:58:12Z X Amy Finan 2000 Pennsylvania Avenue NW 7000 Washington DC 20006 40137500 0 X www.sabin.org X 1994 MD To make vaccines more accessible, enable innovation and expand immunization. 11 11 84 0 0 0 33467236 676914 0 39331759 78167 128827 0 0 33545403 40137500 3127948 3064520 0 0 7783266 9595310 0 0 278228 20371513 29506935 31282727 42166765 2262676 -2029265 21704675 15385516 7350391 3076842 14354284 12308674 X To make vaccines more accessible, enable innovation and expand immunization across the globe. 0 0 27130238 31913858 Vaccine Research & DevelopmentThe Sabin Vaccine Institute supports innovative technologies and approaches in vaccine research and development to combat infectious and emerging threats to global health. Sabin's Research & Development strategy is to advance the development of vaccine candidates that have demonstrated early scientific value but have little commercial value, targeting diseases that impact the world's most vulnerable populations. Sabin leverages the expertise of partners in the academic, public, and private sectors, and promotes open-source research. Ebola has taken the lives of more than 15,000 people in the last many years. To protect communities across the globe from the critical threat posed by Ebola and the closely related, but lesser known, Marburg virus, Sabin is currently developing vaccines for Sudan ebolavirus and Marburg virus diseases based on technology licensed from GSK. The prophylactic vaccine candidates are based on GSK's proprietary ChAd3 platform. In 2019, the U.S. Health and Human Services' Biomedical Advanced Research and Development Authority awarded Sabin a multi-year development contract to advance development of the Marburg and Sudan Ebola vaccines. 10155299 3064520 7417901 Global ImmunizationDespite scientific advances and international support, 1.5 million people still die each year from diseases that could have been prevented by immunization. Sabin has a vision of a future free from such preventable diseases. Reaching this goal requires efficient vaccine distribution, broad vaccine uptake and equitable access to vaccination services. Through advocacy, capacity development and social, behavioral, and epidemiological research, Sabin advances evidence-based strategies for improved distribution and uptake of vaccines. Sabin's Global Immunization programs focus on turning vaccines into vaccinations by ceding power, resources, and decision-making to community and national stakeholders. They build consensus to mobilize action through stakeholder consortiums and convenings; strengthen the capabilities of local immunization professionals to deliver vaccinations to remote and hard-to-reach settings; co-design implementation research studies with community-based investigators to highlight barriers for vaccine uptake; and apply epidemiology for disease surveillance as well as optimizing vaccine use. Sabin's Boost global community enables immunization professionals to connect with peers and experts, learn skills that build capacity and advance careers, and lead immunization programs in challenging contexts. Sabin's Vaccine Acceptance & Delivery workstream focuses on understanding the social drivers of vaccination decisions to improve uptake and confidence. Sabin's Applied Epidemiology team improves disease outcomes by generating essential epidemiological data for well-designed and efficiently implemented immunization programs and creating cost-effective diagnostics for diseases such as typhoid. Through a variety of mechanisms including the Global HPV Consortium and the Coalition Against Typhoid, Sabin brings together researchers, government officials, immunization specialists, and other stakeholders to support the introduction and expansion of new under-utilized vaccines. 37285537 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 1 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 34 0 1 84 1 0 0 0 0 0 0 0 0 0 0 0 0 X 11 11 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD DC NY CA FL WA X The Organization 2406059555 2000 Pennsylvania Ave NW Suite 700 Washington DC 20006 Adegbola Richard Trustee 2.00 X 0 0 0 Baylor Norman Trustee 2.00 X 0 0 0 Djibo Yacine Trustee 2.00 X 0 0 0 Fox Elizabeth Trustee 2.00 X 0 0 0 Hoos Axel Trustee 2.00 X 0 0 0 Libson Jeffrey Trustee, Secretary 2.00 X X 0 0 0 Omer Saad Trustee 2.00 X 0 0 0 Rabinovich Regina Trustee, Chair 2.00 X X 0 0 0 Salisbury David Trustee 2.00 X 0 0 0 Shea Jacqueline Trustee, Treasurer 2.00 X X 0 0 0 Suzich JoAnn Trustee 2.00 X 0 0 0 Finan Amy CEO 40.00 X 503726 0 41728 Gupta Anuradha President 40.00 X 237447 0 29755 DeLeon Kiju CFO 40.00 X 334456 0 31335 King Thomas VP, Nonclinical 40.00 X 316466 0 54173 Vert-Wong Ekaterina VP, Portfolio & Alliance M 40.00 X 312948 0 54739 Garrett Denise VP, Applied Epidemiology 40.00 X 293579 0 36554 Williams Michelle VP, Operations and HR 40.00 X 277693 0 30466 Lopez Antonio Gonzalez VP 40.00 X 246356 0 32186 2522671 0 310936 33 0 1 0 Reithera SRL Via di Castel Romano 100 Rome IT 00128 Bulk drug substance production for Ebola 13518580 Texas Biomedical Research Institute 8715 W Military Dr San Antonio TX 78227 Immunogenicity and efficacy testing for 3995744 PPD Development 26361 Network Place Chicago IL 60673 Regulatory support services and clinical 2061235 Batelle Memorial Institute Dept L 998 Columbus OH 43260 Clinical trial tests for R&D program 1605243 BDO One International Place 4th Floor Boston MA 02110 Quality Management for R&D program 520250 14 20355 656559 676914 Federal & Other Contracts 900099 39331759 39331759 39331759 98622 98622 30205 0 30205 30205 30205 40137500 39331759 0 128827 X 525567 525567 5000 5000 2533953 2533953 1178448 866981 280231 31236 6957947 5270458 1500062 187427 214132 108757 100666 4709 718514 364929 337782 15803 526269 268106 241952 16211 198387 120348 78039 22340 22340 24662142 24436214 221098 4830 45431 14899 30532 262141 159836 100583 1722 110777 39597 70272 908 273746 273746 624583 548030 66375 10178 1506570 1436164 70406 429297 252600 176697 147001 115619 31382 Loss on lease terminati 780000 780000 Recruitment 200191 170473 29514 204 Dues/subscriptions 148679 41486 102193 5000 Miscellaneous 95604 6474 89130 46 46 42166765 37285537 4603000 278228 1506086 1511941 7361995 5004912 9587532 6443274 89556 11310 506438 306415 1721954 1168084 730567 553870 444763 523902 1201953 949353 275785 80539 21704675 15385516 5814295 1711692 1536096 1365150 7350391 3076842 X 4311941 5567087 10042343 6741587 14354284 12308674 21704675 15385516 -2029265 -16345 0 X X 0 1 X 1 0 X 9462400 23177961 26883038 33467236 676914 93667549 9462400 23177961 26883038 33467236 676914 93667549 33206402 60461147 147130 22343 29272 64893 98622 362260 17077 17077 94046886 39331759 0.64290 0.60870 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 42166765 42166765 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 108 161 269 250000 250000 250000 250000 1000000 1500000 1192938 737973 454965 529016 430111 98905 553870 Deferred compensation liability 523902 Lease liability - operating lease 61248 Lease termination liability 780000 1365150 X 40480347 -16345 359192 342847 40137500 0 40137500 42525957 359192 359192 42166765 0 42166765 Part X, Line 2: Management evaluated the Institute's tax positions and concluded that the Institute's financial statements do not include any uncertain tax positions. 0 Central America and the Caribbean 0 0 Grants to recipients located in region Vaccine Acceptance Small Grants Program awardee 4916 East Asia and the Pacific 0 0 Grants to recipients located in region Health Journalism, Vaccine research grant, Vaccine study and intervention and fellowship grants 175067 South America 0 0 Grants to recipients located in region Epidemiology study site/Vaccine Acceptance journalist mentoring grant 373439 South Asia 0 0 Grants to recipients located in region Epidemiology study site, Vaccine Acceptance Small Grants Program awardee, Vaccine study and intervention, Zero Dose Children grant, Vaccine Acceptance Small Grants Program awardee and fellowship grants 1719479 Sub-Saharan Africa 0 0 Grants to recipients located in region Vaccine Acceptance Small Grants Program awardee and fellowship grants. 259802 Europe (Including Iceland & Greenland) 0 0 Grants to recipients located in region Fellowships and Grants 1250 0 0 0 0 0 0 2533953 0 2533953 East Asia and the Pacific Health Journalism 103067 0 EFT East Asia and the Pacific Vaccine research grant 63000 0 EFT South America Epidemiology study site 342419 0 EFT South America Vaccine Acceptance journalist mentoring grant 31020 0 EFT South Asia Epidemiology study site 1052917 0 EFT South Asia Epidemiology study site 320000 0 EFT South Asia Epidemiology study site 130000 0 EFT South Asia Vaccine Acceptance Small Grants Program awardee 78298 0 EFT South Asia Vaccine study and intervention 62947 0 EFT South Asia Zero Dose Children grant 62467 0 EFT Sub-Saharan Africa Vaccine study and intervention 62993 0 EFT Sub-Saharan Africa Vaccine study and intervention 62896 0 EFT 12 0 Fellowships and Grants East Asia and the Pacific 2 4000 EFT Vaccine Acceptance Small Grants Program awardee Fellowships and Grants Central America and the Caribbean 1 1250 EFT Fellowships and Grants South Asia 4 3500 EFT Fellowships and Grants Sub-Saharan Africa 41 124596 EFT 0 0 0 0 0 0 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). 1 International Women's Media Foundation 1625 K Street NW Suite 1275 Washington DC 20006 521648942 501(c)(3) 75000 0 Vaccine Acceptance journalist mentoring grant IVAC 615 N Wolfe Street Baltimore MD 21205 520595110 501(c)(3) 78844 0 Submission and approval of midline reports Loma Linda University Cash Concentration 11065 Campus Street Loma Linda CA 92350 951816009 501(c)(3) 11870 0 Vaccine Acceptance Small Grants Program awardee Massachusetts General Hospital 55 Fruit Street GRJ 504 Boston MA 02114 041564655 501(c)(3) 60000 0 Epidemiology study site Stanford PO Box 44253 San Francisco CA 94144 941156365 501(c)(3) 254867 0 Outbreak modeling University Of California Davis One Shields Ave Davis CA 95616 946036494 501(c)(3) 35000 0 Epidemiology study site 6 0 Covid Fellowship 1 5000 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). X X X X X X 0 0 0 0 0 0 0 0 0 Finan Amy CEO 441106 0 56000 0 6620 0 10740 0 30988 0 545454 0 0 0 King Thomas VP, Nonclinical 291834 0 20000 0 4632 0 12017 0 42156 0 370639 0 0 0 Vert-Wong Ekaterina VP, Portfolio & Alliance M 290376 0 20000 0 2572 0 12017 0 42722 0 367687 0 0 0 DeLeon Kiju CFO 313638 0 15000 0 5818 0 12265 0 19070 0 365791 0 0 0 Garrett Denise VP, Applied Epidemiology 265528 0 18000 0 10051 0 10574 0 25980 0 330133 0 0 0 Williams Michelle VP, Operations and HR 263974 0 11000 0 2719 0 10674 0 19792 0 308159 0 0 0 Lopez Antonio Gonzalez VP 243484 0 0 0 2872 0 5833 0 26353 0 278542 0 0 0 Gupta Anuradha President 233131 0 0 0 4316 0 2400 0 27355 0 267202 0 0 0 Form 990, Part VI, Section B, line 11b The Form 990 is prepared by an outside tax accounting firm based on independently audited financial statements. The Form 990 is then reviewed by the Controller and the CFO. Then the Form 990 is presented to the CEO and Finance Committee for their review and approval. Finally it is presented to the full Board of Trustees for their review before filing. Form 990, Part VI, Section B, line 12c Sabin's management, Board Chair and Governance Committee are reponsible for ensuring the conflict of interest policy is up-to-date and adhered to by the Trustees. Form 990, Part VI, Section B, line 15 Compensation of officers and/or key employees is set in consultation with input from the Board, Executive Committe or Chair as appropriate. Sabin uses a mix of data points including: independent salary surveys; comparable pay by similar organizations; compensation firms and our own internal pay scale. Form 990, Part VI, Section C, line 19 Governing documents (upon request), conflict of interest policy (upon request), and financial statement and Form 990 (Sabin's website). Form 990, Part IX, line 11g Transcription/translation service: Program service expenses 40,574. Management and general expenses 47. Fundraising expenses 0. Total expenses 40,621. Consultants: Program service expenses 2,617,900. Management and general expenses 215,095. Fundraising expenses 4,830. Total expenses 2,837,825. Contractor: Program service expenses 21,777,740. Management and general expenses 5,956. Fundraising expenses 0. Total expenses 21,783,696. Form 990, Part XII, Line 2c: The Organization has a Finance Committee that assumes responsibility for oversight of the audit. This process is consistent with prior years.